Drug

Lypressin

As of the edition of 20 October 2026, Lypressin is a protein: marketed, first approved in 1982 (US); acts on AVPR1A, AVPR1B and AVPR2; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Protein
Brand name
Diapid
First approved
1 January 1982 (US)
Approvals on record
1 in 1 region
Holder of the most recent approval
Novartis

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Targets

GeneProteinUniProt
AVPR2Vasopressin V2 receptorP30518
AVPR1AVasopressin V1a receptorP37288
AVPR1BVasopressin V1b receptorP47901

Who has held its approvals

CompanyRoleYears
NovartisApplicant